Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
|Articles|August 1, 2005
Cut Casts-and Costs
At over $750, cast saws are expensive. Save money by making one yourself. Simply buy a vibrating detail sander (available from your local woodworking supply store), and fit it with a tile-cutting blade. Total cost: about $75.
Advertisement
At over $750, cast saws are expensive. Save money by making one yourself. Simply buy a vibrating detail sander (available from your local woodworking supply store), and fit it with a tile-cutting blade. Total cost: about $75.
--Mike Niziol, MD
Freeville, NY
Advertisement
Related to this article
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
5